Drug intelligence / Profile preview

T4P1001

Development stage: Phase 1
Lead developer: Cognivia
Administration: Oral

Overview

T4P1001 is a specialized placebo capsule developed by Tools4Patient (now Cognivia) for use in clinical research. It is specifically designed to study the placebo response in patients with chronic pain conditions, such as peripheral neuropathic pain and osteoarthritis. T4P1001 is utilized as a tool to develop and validate the Placebell technology, a machine learning-based predictive algorithm that characterizes individual patients' placebo responsiveness based on personality traits, beliefs, and perceptions. In clinical trials, it has been administered as an add-on therapy to standard analgesic treatments to help researchers differentiate between drug effects and placebo effects.

Other names: T4P1001-Tools4PatientT-4P1001-Tools4PatientT 4P1001-Tools4Patient

Beyond the preview

Go deeper on T4P1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T4P1001.

Explore the full profile